Allergan PLC. (AGN) Stock Rating Reaffirmed by Wells Fargo & Company

Wells Fargo & Company reissued their outperform rating on shares of Allergan PLC. (NYSE:AGN) in a research report report published on Monday.

A number of other research analysts also recently commented on AGN. UBS AG reaffirmed a buy rating and set a $275.00 target price on shares of Allergan PLC. in a report on Monday, May 15th. Sanford C. Bernstein reaffirmed an outperform rating on shares of Allergan PLC. in a report on Thursday, May 25th. ValuEngine downgraded Allergan PLC. from a buy rating to a hold rating in a report on Friday, June 2nd. Cowen and Company set a $400.00 price target on Allergan PLC. and gave the stock a buy rating in a report on Thursday, June 8th. Finally, Mizuho cut their price target on Allergan PLC. from $275.00 to $267.00 and set a buy rating on the stock in a report on Friday, June 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $274.69.

Allergan PLC. (NYSE AGN) opened at 223.58 on Monday. The firm has a 50-day moving average price of $232.72 and a 200 day moving average price of $236.77. The firm has a market capitalization of $74.74 billion, a P/E ratio of 6.81 and a beta of 1.18. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter last year, the firm earned $3.35 EPS. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. Analysts forecast that Allergan PLC. will post $16.25 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Allergan PLC. (AGN) Stock Rating Reaffirmed by Wells Fargo & Company” was originally reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://baseballnewssource.com/markets/allergan-plc-agn-stock-rating-reaffirmed-by-wells-fargo-company/1634296.html.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

Several hedge funds and other institutional investors have recently modified their holdings of AGN. Vanguard Group Inc. boosted its position in shares of Allergan PLC. by 2.2% in the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after buying an additional 482,220 shares during the period. Northern Trust Corp boosted its position in shares of Allergan PLC. by 8.8% in the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after buying an additional 364,722 shares during the period. Veritas Asset Management LLP acquired a new stake in shares of Allergan PLC. in the first quarter worth $761,339,000. Edgewood Management LLC boosted its position in shares of Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after buying an additional 178,055 shares during the period. Finally, Epoch Investment Partners Inc. boosted its position in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after buying an additional 73,081 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.